News

24/7 Wall St.1h
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (April 2025)
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
STAT5h
When should six drugs count as one? The answer could be a big deal for pharma companies
A unique Novo Nordisk legal challenge to the Medicare drug pricing program could have big implications for the pharma ...
Wall Street Trims Ratings for Novo Nordisk Stock, as Ozempic’s Competition Grows
Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...
Novo Nordisk: A Price Too Low To Ignore
Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.
STAT6m
Pharmalittle: We’re reading about a Novo challenge to Medicare talks, a scuttled FDA office, and more
Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...
Novo Nordisk warns consumers about counterfeit versions of Ozempic in US
Danish drugmaker Novo Nordisk said on Monday several hundred counterfeit units of its diabetes drug Ozempic were being ...
Fake Ozempic drugs found in US drug supply, FDA warns
The FDA has issued a warning about counterfeit Ozempic medications, sharing the lot numbers and serial numbers of products ...
Patients Cut Off From Cheaper Obesity Drugs as the F.D.A. Halts Sales of Copycats
U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...